COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies.

COMPASS Pathways, a biotechnology company dedicated to innovation in mental health, gained $285 million in private funding to research psychedelics, Behavioral Health Business reports. This amount ...

If experiencing a mental health problem were plotted like a line on a graph, it might look like a low-level shallow wave, or a dramatic fall and rise with a few roller coaster bumps scattered in ...

In the decades following deinstitutionalization, the U.S. has yet to find an effective model of a comprehensive behavioral ...

With over 30 years of experience in the mental health field, I offer outpatient therapy services to older adolescents and adults. While I work with a wide range of mental health concerns, my primary ...

Resurgence Behavioral Health has published a new educational resource titled “Attending Inpatient Rehab for Couples with ...

Psychiatric genetics offers insights into the complex, heritable nature of mental illnesses such as schizophrenia and bipolar ...

Systems of oppression like racism, sexism, and classism lead to poor health outcomes. These factors are a source of poor mental health and have particular implications for pregnant and birthing people ...

With over 14 years of experience as a Licensed Mental Health Counselor (LMHC), I am deeply committed to helping individuals navigate life's challenges and achieve their fullest potential. My approach ...